HER2 and central nervous system metastasis in patients with breast cancer

Clinical Breast Cancer

Volumn 5, Issue 3, 2004, Pages 232-234

  Montemurro, Filippo ^a   Sarotto, Ivana ^a   Casorzo, Laura ^a   Pisacane, Alberto ^a   Aglietta, Massimo ^a   De Rosa, Giovanni ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Ductal carcinoma; HER2 neu; Trastuzumab

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; AXILLARY LYMPH NODE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER INFILTRATION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC RISK; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LIVER METASTASIS; LYMPH NODE METASTASIS; MOLECULAR CLONING; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY;

EID: 12344254977     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.027     Document Type: Article

References (19)

1. Kim YS, Konoplev SN, Montemurro F, et al. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 2001; 7:4008-4012.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
3. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972-2977.
4. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19:2587-2595.
5. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:1800-1808.
6. Montemurro F, Choa G, Faggiuolo R, et al. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004; 66:38-45.
7. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000; 18:2349-2351.
8. Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003; 14:1072-1077.
9. Fornier M, Risio M, Van Poznak C, et al. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Huntingt 2002; 16:1340-1342.
10. Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK, et al. Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 2003; 127:1451-1457.
11. Lonn U, Lonn S, Nilsson B, et al. Intratumoral heterogeneity for amplified genes in human breast carcinoma. Int J Cancer 1994; 58:40-45.
12. Pertschuk LP, Axiotis CA, Feldman JG, et al. Marked Intratumoral heterogeneity of the proto-oncogene Her-2/neu determined by three different detection systems. Breast J 1999; 5:369-374.
13. Glockner S, Buurman H, Kleeberger W, et al. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002; 82:1419-1426.
14. Kneuper-Hall R, Labarowski G, Metzner-Sadurski J, et al. HER-2/neu intratumoral heterogeneity as analyzed by FISH: a non-apparent entity except in mixed histology tumors. Breast Cancer Res Treat 2003; 82(suppl):S98 (Abstract #416).
15. Montemurro F, Valabrega G, Aglietta M. Trastuzumab-based combination therapy for breast cancer. Exp Opin Pharmacother 2004; 5:81-96.
16. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13:1036-1043.
17. Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93:1141-1146.
18. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001; 61:5345-5348.
19. Risio M, De Rosa G, Sarotto I, et al. HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int J Oncol 2003; 23:1381-1387.